Company intelligence / Profile preview
Exacis Biotherapeutics
Cambridge, Massachusetts, United Statesexacis.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Exacis Biotherapeutics developed preclinical-stage engineered NK and T cell therapies from iPSCs using proprietary mRNA-based, virus-free reprogramming and gene-editing technologies. These next-generation off-the-shelf cell therapies demonstrated promising in vitro features, such as improved tumor-killing and immune stealth, but do not have clinical trial results to date. The full platform and pipeline were acquired by Eterna Therapeutics in 2023.[2][6]
- Therapeutic areas
- Oncology
- Modalities
- Induced pluripotent stem cell derived therapyCell therapyNK cell therapyT cell receptor engineered T cell therapymRNA-based drugs
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Factor Bioscience (mRNA technology in-licensing)CCRM (manufacturing and investment, 2021)[5]
Beyond the preview
Go deeper on Exacis Biotherapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Exacis Biotherapeutics.